CDT Equity Inc. (CDTTW) — Current Report

AI-Powered SEC Filing Analysis

← All CDTTW filings

Want the newest filings?

This analysis covers the filing from 2026-04-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Earlier Current Report filings

Filed: 2026-03-25
  • CDT Equity Inc. has announced a 1-for-25 reverse stock split, which will reduce the number of outstanding shares and potentially increase the stock price.
  • The reverse stock split is expected to become effective on March 26, 2026, and the company's common stock will begin trading on a split-adjusted basis on March 27, 2026.
  • No fractional shares will be issued as a result of the reverse split, and stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment instead.
Filed: 2026-03-18
  • The company is seeking shareholder approval to issue additional shares of common stock, which could dilute existing shareholders.
  • The company plans to pursue a reverse stock split, which could improve the stock's trading price and liquidity.
  • The company is proposing to redomicile from Delaware to the Cayman Islands, which could impact shareholder rights and tax implications.
Filed: 2026-03-09
  • CDT Equity Inc. has amended its existing equity line of credit (ELOC) with an institutional investor, lowering the floor price to $0.60 per share, which could increase the potential maximum number of shares issuable under the ELOC.
  • The company has issued a senior secured convertible promissory note with a principal amount of up to $555,556, which is convertible into common stock subject to shareholder approval.
  • The convertible note is secured by certain company assets and further secured by a guaranty agreement, providing additional assurances for the investor.
Filed: 2026-02-24
  • CDT Equity Inc. has acquired a 20% stake in Sarborg Limited, a Cayman Islands company, for a consideration of shares of its common stock and pre-funded warrants.
  • The company has also extended its consulting agreement with NJS Foresight Bio-Advisory, LLC for an additional 12 months, with a one-time fixed retainer payment in the form of shares of its common stock.
  • The transactions indicate that CDT Equity Inc. is actively pursuing growth opportunities through strategic investments and partnerships.
Filed: 2026-01-02
  • CDT Equity Inc. entered into two material consulting agreements with Thesprogen, PC and NJS Foresight Bio-Advisory, LLC to optimize its pre-clinical development and out-licensing strategy for its asset portfolio.
  • As consideration for the consulting agreements, CDT issued a total of 213,288 shares of its common stock valued at the closing price immediately preceding the execution of the agreements.
  • The NJS agreement includes a one-time fixed retainer of $150,000 and an 8% commission fee on the total announced value of any out-licensing transactions, partnerships or definitive agreements executed during the 12-month term.

Other reports for CDT Equity Inc.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.